diagnost diversif clear path biopharma
expect growth continu initi
initi coverag interpac diagnost group inc outperform
rate price target view idxg emerg growth stori
oncolog diagnost space recent enter new high growth market
acquisit biopharma test busi continu gain traction
thygenext thyramir improv payor coverag bolster balanc
sheet strateg investor may support addit busi develop
acceler path profit manag achiev goal posit cash
flow view idxg share may enjoy upward re-valu trade
line peer group revenu pt base multipl
revenu
diversif reduc reimburs risk none newli acquir
biopharma busi subject commerci reimburs medicar
payment forecast call biopharma account total revenu
believ unit offer safe reimburs
headwind relat futur pama discuss broader us healthcar reform
chang medicar coverag
healthi end growth cancer drug research estim
number cancer drug clinic studi increas manag
expand test menu commerci leadership believ biopharma
eventu grow line overal market
gain share thyroid competitor afirma sale increas
compar growth total idxg sale idxg break sale
product disclos pancragen sale roughli flat impli
thygenext thyramir revenu grew significantli faster
reflex test good market defin favor practic guidelin
model reduc volum exploratori surgeri limit util
diagnost paramet clinic assess cytopatholog believ
market support one winner
pipelin expans believ acquisit may appropri
strategi expand endocrinolog gi franchis would
anticip transact includ commerci infrastructur provid
immedi contribut revenu rather technology-rel develop
year price histori idxg
focu sell
interpac diagnost group inc
stage
thyroid pancreat
provid diagnost test servic
pharmaceut compani primarili
analyst certif import disclosur see disclosur
believ recent acquisit biopharma test servic
combin growth compani thyroid test busi
result idxg achiev posit cash flow
could drive upward revalu stock furthermor
expect bolt-on acquisit remain import part
idxg busi model could improv oper leverag
compani oncolog endocrinolog gastrointestin
disord commerci channel term organ growth
believ compani two core marketsoncolog clinic trial
stage indetermin thyroid nodulesar fundament
good market stabl price grow demand
support growth potenti market share
biopharma unit contribut revenu support
growth next year maintain market share
clinic diagnost sale increas annual driven
improv complianc guidelin molecular test
revenu contribut barregen pipelin program
contribut addit
expans sale forc drive demand
thygenext tyramir
becom contract thygenext tyramir
one nation insur compani
state target achiev posit cash flow
bolt-on acquisit acceler revenu growth
addit offer commerci oper leverag upsid
revenu outlook
new leadership biopharma result faster expect
penetr exist custom result growth
model assum gross margin bioharma unit better
expect merger synergi higher margin could reduc
time profit
biopharma fail achiev expect growth due
medicar
thygenext tyramir molecular thyroid assay
result slower expect market growth
futur acquisit destroy sharehold valu either poor
strateg fit inappropri purchas price
pt base ev-to-sal analysi assum multipl estim revenu million share
outstand peer group high-growth diagnost compani multipl around due limit scale idxg
commerci oper neg cash flow
risk idxg includ merger integr purchas biopharma unit sharehold concentr relat ampersand
capit partner ownership stake technolog obsolesc relat current relianc fish test biopharma
unit new product adopt includ respridx barregen
note view idgx stock trade specul appropri risk-toler investor
initi outperform pt
initi coverag interpac diagnost group inc outperform rate
price target view idxg emerg growth stori
oncolog diagnost space recent enter new high growth market
acquisit biopharma test busi continu gain traction thygenext
 thyramir improv payor coverag bolster balanc sheet
strateg investor may support addit busi develop acceler
path profit
manag success achiev goal posit cash flow
view idxg share may enjoy upward re-valu trade line peer
group revenu view success integr recent acquisit cancer
genet biopharma test unit includ target growth first
month follow close transact primari driver time idxg
transit posit cash flow wed note manag amass solid track record
identifi accret bolt-on transact includ asset rosetta genom
asuragen redpath
price target idxg share base primarili ev-to-sal analysi
assum multipl appli revenu estim divid
entri pharma test diversifi revenu reduc reimburs exposur
idxg valid five clinic assay revenu growth driven primarili
thyroid franchis thyramir thygenx acquisit cancer
genet biopharma unit juli idxg ad viabl second leg growth
busi model acceler path profit importantli
reduc compani exposur potenti reimburs risk none
pharmaceut busi subject commerci reimburs medicar payment
forecast call biopharma test unit account total revenu
believ unit offer safe reimburs headwind
relat futur pama discuss broader us healthcar reform chang
posit secular growth trend oncolog drug develop
awar reliabl statist pace growth pharmaceut
spend cancer research view growth number immun oncolog drug
clinic trial good proxi base data cancer research institut estim
number drug increas manag expand test menu
commerci leadership believ biopharma eventu grow line
note pleas see initi report exact scienc corpor exas-outperform
share gain thyroid test remain primari pillar growth
view thyroid fna reflex test good market defin favor practic
pharmacoeconom model reduc volum exploratori surgeri limit
util diagnost paramet clinic assess cytopatholog
first mover group veracyt afirma maintain largest market share
revenu roughli howev believ idxg
gain share growth afirma compar growth total
idxg sale period idxg break sale product
disclos pancragen sale roughli flat impli thygenext thyramir
revenu grew significantli faster long term believ market
support one winner base clear treatment guidelin describ valu
molecular test without recommend use one specif test
outperform rate idxg share base least part view medic
market bad market function qualiti clinician support test
measur believ molecular test follow indetermin fna good market
support nccn american thyroid associ ata guidelin
recommend use molecular test follow bethesda categori iii-iv fna
regardless clinic characterist without specifi molecular test
use reflex test broad languag allow idxg thygenx thyramir
gain broad insur coverag plan million cover live within four
year launch expect patient access support continu healthi sale growth
annual next year idxg expand sale forc call
growth acquisit like continu
forecast call expens increas slower rate revenu
oper expens given rel limit access capit privat
held diagnost compani believ certain circumst expand idxg
product portfolio may achiev quickli cheapli acquisit
intern dparticularli new market specif believ acquisit may
appropri strategi expand endocrinolog gi franchis would
anticip transact includ commerci infrastructur provid immedi
contribut revenu rather technology-rel develop stage asset
price target idxg share base primarili ev-to-sal multipl
project revenu see exhibit view ev-to-sal appropri
methodolog compani transit sustain profit common valuat
metric diagnost test compani
mention view idxg product busi model enjoy differenti
base clinic util data potenti maintain premium price time
view test servic refer lab labcorp
view closest compar public compani base competit
product diagnosi thyroid cancer follow indetermin fna result
current trade consensu revenu ev-to-revenu basi
believ market reward compani clear path profit attract
economi scale higher ev-to-revenu multipl idxg build scale expect
highlight exhibit compani larger scale serv market
genom health trade multipl
sale view aspir valuat idxg upon achiev greater scale
pt base multipl appli revenu estim
divid post-acquisit share outstand million view
multipl repres discount appropri given
idxg earlier stage develop
exhibit ev-to-sal peer group analysi
oppenheim co estim ghdx idxg factset estim
view idxg primarili revenu growth stori quarterli financi result
offer greatest opportun short-term stock appreci view
sever oper mileston next month help fuel long-term
current portfolio diagnost test assembl busi develop
expect idxg continu look extern busi develop opportun
expand compani product portfolio mention invest thesi
expect idxg achiev posit cash flow begin strateg product
acquisit leverag idxg current sale forc could provid better oper
leverag pull forward expect compani achiev posit ep
compani document oppenheim co estim
companypricetickernet cashmarket capenterpris salesev/salesexact importancestrateg product posit cash flowmid commerci partnership biomark thyroid oppenheim co inc estim interpac diagnost group
addit near-term catalyst includ potenti add biomark exist product
includ thyroid assay sign commerci partnership barregen present
addit clinic data compani commercial-stag program
describ exhibit
corpor histori busi model
idxg form contract sale organ cso grew becom
pdi inc execut offic parsippani nj cso expand next
year driven greater flexibl pharmaceut compani outsourc
commerci servic margin poor pdi never gener sustain posit cash
flow prior manag began acquir diagnost busi strategi
diversifi revenu higher-margin diagnost product busi acquisit
includ asuragen redpath integr technolog brought
diagnost product serv primari sourc idxg current revenu
idxg acceler restructur divest pdi cso busi
publici healthcar commun group initi transit
senior leadership decemb appoint stover ceo
subsequ nearli senior leadership replac compani
recapit balanc sheet result elimin outstand debt
take recent acquisit biopharma busi signific equiti
invest ampersand capit believ idxg transit
maxim valu legaci asset foscus diversif product portfolio
term current busi model idxg commercial-stag molecular diagnost
compani focus primarili sell premium-pr prognost predict test
patient suspect risk cancer three teststhygenext thyramir
pancragenaccount nearli idxg revenu summar exhibit idxg
also offer respridx barregen test design improv patient
manag reduc morbid associ unnecessari surgeri lower
compani document oppenheim co inc estim
pancragen design provid differenti diagnosi patient pancreat cyst
group low high risk develop pancreat cancer american societi
gastroenterolog endoscopi asg guidelin includ recommend use
pancragen test offer indetermin diagnosi pancragen
idxg matur commerci franchis account roughli sale
compani sell two thyroid cancer diagnost design use combin
contemporari clinic practic patient indetermin cytopatholog thyroid
fine needl aspir fna often undergo surgeri remov part thyroid obtain
accur diagnosi approxim thyroid nodul prove benign
thyramir optim rule test thygenext optim rule
test thyroid cancer patient indetermin cytopatholog thyroid cancer
franchis fastest grow segment idxg portfolio base establish nccn
guidelin drive increas complianc use molecular test prior surgeri
result growth overal market favor competit dynam rel
afirma due significantli better posit predict valu ppv
confirm diagnosi thyroid cancer
respridx assess metastasi versu second primari tumor lung cancer
patient barregen assess risk develop esophag cancer
barrett esophagu earli commerci launch limit reimburs coverag
current includ econom product financi forecast
revisit assumpt follow public addit clinic util data
lastli juli compani acquir biopharma test busi cancer
genet view near-term busi model rel simpl former parent
compani financi distress caus exist custom divert new
contract financi stabl competitor transit busi idxg
manag expect recaptur market share exist custom lead
plu one-tim step demand intermedi term view oncolog
clinic trial market healthi expect end-market growth
structur biopharma acquisit
idxg acquir cancer genet biopharma unit juli gross purchas price
plu addit liabil transact valu unit roughli
revenu run rate concurr transact ampersand capit
partner agre invest idxg purchas common prefer
stock close transact upon sharehold approv
expect octob
unit provid assay develop clinic test servic pharmaceut
industri primarili oncolog drug develop includ fish test test
level immune-oncolog clinic trial cancer genet financi
break segment revenu idxg manag believ growth busi
flat recent quarter due larg measur financi distress cancer
breakdown purchas price summar exhibit promissori
note carri interest rate expect repaid proce
second tranch capit ampersand
exhibit breakdown biopharma busi gross purchas price
compani document oppenheim co inc estim
term profit busi manag expect biopharma unit
achiev posit cash flow base project first year driven
stronger balanc sheet invest expand sale team biopharma
regain market share exist custom
take pharmaceut compani sensit financi posit contract
ensur continu servic believ financi distress cancer genet neg
impact growth healthier balanc sheet dixg believ biopharma
return growth industri growth rate
idxg fund biopharma acquisit busi seri
prefer stock offer ampersand capit partner structur outlin
exhibit
compani document oppenheim co estim
juli idxg issu seri convert prefer share ampersand
seri convert prefer stock vote date month
juli issuanc date annual sharehold meet whichev
sooner initi seri convert prefer automat convert
share common stock convers valu per share
idxg annual stockhold meet schedul octob upon
stockhold approv compani issu seri convert prefer share
convert share common stock per share
notabl seri stock directli convert common stock
convert seri prefer stock subsequ convert common
stock dividend accrual rate seri stock issu
benefit seri prefer stock holder includ seri prefer stock
holder must give written consent substanti chang board one
sharehold entiti own least share series-a prefer stock abl
design one director board liquid case prefer stock holder
descriptionvaluewir balanc undisclos promissori account payabl nj nc accru valu prefer stockshar issuedvalu share issuediniti close seri seri second close seri idxg outperform
given prioriti claim asset three year initi close prefer
stockhold may redeem seri stock common stock
manag expect ampersand hold econom interest seri
prefer stock convert common stock near term order captur
coupon note idxg forc convers seri prefer stock
event compani complet offer common stock warrant
price greater
biopharma busi focus nich high touch opportun
idxg acquir laboratori equip client relationship intellectu properti access
lab technician lab manag two lab divis primarili provid fish flow
cytometri molecular test anatom patholog cytogenet servic
pharmaceut biotech compani servic includ assay develop
analysi sampl clinic trial way exampl test statu
merck clinic trial keytruda among compani larger product line
typic contract may begin custom alreadi internally-develop
homebrew test need standard potenti ivd vitro diagnost test
requir improv analyt perform support futur clinic trial de-
fee data report fee scientif servic assay develop assay
optim assay valid fee sampl analysi
cancer genet cgix idxg disclos price per-sampl basi
expect averag around fish molecular servic
slightli averag
busi model differenti base high degre custom rel
small projectsa typic contract rang believ
compani face limit direct competit market larger specialti lab
neogenom focus primarili potenti contract tradit cro
quintil covanc offer level support custom
data manag unlik compani foundat medicin
biopharma unit cgix acquir idxg offer proprietari
take believ biopharma posit attract nich market
servic small percentag total drug develop cost work often
materi impact qualiti diagnost data believ busi
enjoy attract gross margin servic price appropri
base discuss manag cgix idxg
custom view econom incent commerci team misalign
incent skew toward gross revenu inadequ account price
begin new leadership cancer genet divis de-bundl
price model provid greater transpar valu servic result
upward re-pric across contract furthermor idxg expect realign econom
incent sale group also includ backlog growth actual revenu
manag goal gross margin eventu exceed base higher
revenu run rate contract re-pric due complex cancer genet segment
report view possibl teas precis current gross margin
base case assum figur around like revisit assumpt
cancer genet manag publicli acknowledg financi distress parent
compani result exist client redirect work altern vendor
outlook idxg base case assum level pent-up demand
exist custom begin reorder biopharma hous within
financi stabl oper idxg day sinc close
transact idxg manag note busi appear stabil
take manag guidanc near-term growth biopharma unit due
exist custom return tradit order pattern expans
biopharma commerci team peopl appear achiev
view acquisit biopharma primarili sourc revenu
diversif view sever potenti avenu oper synergi
biopharma unit current manag sever biolog sampl repositori facil
north carolina extent idxg access sampl clinic sampl
accru cancer genet idxg may abl acceler new product develop
gastrointestin disord includ pancreat cancer well acceler work
addit idxg believ biopharma unit import expertis molecular
test may applic current commerci test stage indetermin
result patient undergo test gi endocrin disord
competit landscap biopharma servic
view diagnost space highli competit sever larger
experienc compani stake biopharma-bas test servic clinic
diagnost test servic idxg newli acquir biopharma unit tradit
focus smaller contract less attract larg specialti
lab technolog patform fish less competit
though view competit pharmaceut segment larg base
reput qualiti sequenc data bioinformat analysi turnaround time
menu services/breadth coverag price secondari consider
custom
believ biopharma servic unit addit differenti includ better
clinic expertis consult servic clinic trial design
addit expans field precis oncolog need clinic
diagnost servic stage develop continu grow well mediat
competit pressur diagnost compani expect sector
biopharma client concentr two area immuno oncolog biomarker-
base target therapeut mostli indic treatment solid tumor
highlight exhibit total number clinical-
stage organ non-profit academ commerci increas
number immun oncolog drug develop increas
core immuno oncolog precis medicin requir
abil understand genet background tumor identifi druggabl target
take expect futur oncolog drug develop shift toward find therapi
treat patient respond inhibitor monotherapi expect
drug develop combin regimen requir complex genet test
understand potenti contribut product
exhibit growth number immuno oncolog drug develop
adapt cancer research institut report
cell therapy/car-t immunomodulatori agent cancer vaccin
common class new agent exhibit
exhibit growth new compound spread across differ modal
tang et al cancer research institut trend global immuno-oncolog landscap natur review drug discoveri
take multipl growth driver immun oncolog drug sale pipelin
expans believ group well posit sustain growth least
next year pipelin matur requir larg late-stag clinic trial
sale top nine fda-approv immuno oncolog drug gener revenu
nearli attribut inhibitor alon see exhibit
exhibit sharp rise immuno oncolog sale driven checkpoint inhibitor
iqvia deal trend immuno-oncolog
parallel increas revenu pharma compani fund dramat
expans clinic trial explor addit solid tumor type may benefit
monotherapi explor combin regimen immun
oncolog drug chemotherapi
result drug continu annual expens well base
data immuno oncolog clinic trial globaldata
estim compound-annual-growth-rate compound annual growth rate immuno oncolog clinic trial
believ reason estim base interest immuno
oncolog realli taken last five year
support view biopharma test servic healthi grow industri
also examin valu small molecul inhibitor context cost
patient valu larg pharmaceut compani
format nodul thyroid gland rel common preval
us popul accord epidemiolog studi publish decemb
issu clinic endocrinolog metabol nodul
classifi benign evalu fine-needl aspir fna biopsi estim
fna gener indetermin result accord larg studi
indetermin cytolog publish august issu nejm furthermor clinic
featur age gender comorbid provid use context
understand risk malign follow indetermin fna mean number
nodul present clinic diagnosi increas age risk aggress malign
appear independ clinic characterist demograph
import studi publish decemb issu journal clinic
endocrinolog metabol entitl influenc patient thyroid nodul
format multinodular thyroid cancer risk research note
number thyroid nodul per patient identifi ultrasound increas steadili age
risk nodul malign decreas age
studi evalu patient ultrasound nodul fna
analysi classifi patient age year six cohort age cancer
preval compar use cytolog histolog measur thyroid nodul
preval older patient annual increas risk
multinodular notabl risk malign age found
decreas annual even normal malign rate per nodul risk
malign higher younger patient age compar oldest
cohort patient age exihibit
exhibit fna malign risk declin
kwong et al influenc patient thyroid nodul format multinodular thyroid cancer risk journal clinic
backdrop challeng diagnosi indetermin fna tradit
cytopatholog molecular test rapidli becom standard care stage
patient follow indetermin biopsi thyroid cancer tend high mutat
burden patient least one known genet mutat howev
specif driver mutat preval among patient
multivari assay explor relationship multipl genet marker
demonstr robust benefit assist differenti diagnosi benign
malign nodul
take multivari assay evalu relationship differ genet variant
unlik demonstr compar perform profil result
signific perform differ commerci differenti
background thyroid cancer diagnosi
accord nation cancer institut nci new case thyroid
cancer last year five-year expect surviv rate thyroid nodul typic
first identifi imag exam ultrasound patient suspect thyroid
nodul diagnos use fna rule malign numer studi
conclud thyroid nodul classifi cytolog benign
nodul malign use bethesda system report thyroid cytopatholog
howev remain equivoc find classifi bethesda
categori cytologyatypia undetermin signific follicular lesion
undetermin signific aus/flu bethesda categori iv cytologyfollicular
neoplasm fn suspici fn sfn usual due overlap cytolog
featur benign malign nodul
follow care indetermin fna result vari lab treat clinician mani
patient refer diagnost surgeri nodul classifi benign
studi thyroid nodul publish decemb issu clinic
endocrinolog metabol report patient indetermin cytolog
underw surgic resect data assess malign rate diagnost surgic
procedur vari across studi gener rang
tool reduc exploratori surgeri signific unmet need could reduc cost
healthcar system reduc patient morbid
multipl compani valid molecular test offer addit diagnost power
combin ultrasound fna mention thyroid cancer
patient present least one genet mutat mutat wide
express benign nodul allow differenti diagnosi indetermin
nodul furthermor algorithm assess relationship express level
numer differ genet variant shown power provid
differenti diagnosi absolut chang one specif marker
four gene mutat common impact confirm nodul
malign braf point mutat guanosin triphosph gtp -bind
ra superfamili gene fusion rearrang ppar rearrang
gene fusion studi publish novemb issu clinic
endocrinolog metabol four marker demonstr specif
depend thyroid histolog howev gene variant identifi
patient suggest need addit marker analysi
associ express marker improv predict power
idxg thygenext dna rna sequencing-bas oncogen panel provid
rule-in analysi high posit predict valu whether patient thyroid nodul
malign thygenext use combin thyramir microrna-bas test
design serv rule-out test confirm nodul benign forgo surgeri
thygenext panel assess common genet alter across nine gene
associ papillari carcinoma follicular carcinoma two common form
thyroid cancer panel provid pcr-base enrich fna biopsi
thyroid nodul well analysi nine region within six thyroid cancer-relev
gene braf tert hra kra nra assay also enrich three
rna fusion transcript gene fusion gene fusion
gene fusion posit result thygenx suggest patient thyroid
cancer candid thyroidectomi patient posit thygenext result
need receiv thyramir test
thyramir rule test avoid surgeri
thyramir design reflex test patient test neg thygenx
confirm surgeri necessari support watch wait follow test panel
thyramir provid posit neg result base
algorithm train mirna express profil histolog benign malign
thygenext thyramir intend use combin stand-alone
evalu perform profil test typic construct view
primari perform assess test cross-sect cohort studi
nodul publish may issu clinic endocrinolog metabol
result demonstr combin sensit ci
specif ci npv ppv
thygenx predecessor test thygenext similar perform profil
thyramir neg residu risk malign author
studi conclud use test could result reduct unnecessari
take thygenext-thyramir combin offer better ppv vs
mani payor may see valu test rule tool believ
stronger ppv import patient clinician worri miss treatabl
acknowledg limit cross-studi comparison data thygenx/
thygenext thyramir appear compar favor valid studi
afirma indetermin nodul publish august issu nejm ppv
npv see exhibit
exhibit thygenext thygenx thyramir better ppv afirma
labcorp agreementaccess indetermin fna
one fundament challeng provid reflex test follow
indetermin fna logist secur sampl deliv test result seamless
manner clinician idxg provid cytopatholog servic work
third-parti lab clinician order thygenext thyramir reflex test
compani relationship labcorp one two primari refer lab
us largest provid esoter test leverag labcorp logist
infrastructur relationship form primarili allow effici report
thygenx thyramir test result clinician labcorp report
electron order network expand agreement unveil march
labcorp specialti lab process fna dianon patholog agre reflex certain
indetermin test idxg addit order thygenext thyramir test
labcorp order system simplifi turn simplifi
take expand relationship labcorp drive referr boost test
volum thygenext thyramir
may idxg launch updat version thygenx somewhat confusingli
brand thygenext mutat analysi expand panel
genet alter analyz platform manag believ expand
panel allow assess aggress diseas maintain strong ppv
npv
take adequ publish data assess perform profil
thygenext believ ad content aggress diseas line life cycl
manag prognost test
thyroid competitiongain ground afirma
view veracyt afirma gec primari competit thygenext thyramir
current market share leader molecular test indetermin thyroid fna
sampl believ two primari competitor viabl commerci
model path publish revenu figur thyroseq believ
product limit market share thygenext thyramir
first compani make signific invest molecular profil
indetermin fna sampl primarili respons develop strong nccn
guidelin recommend molecular test altern exploratori surgeri
first mover group veracyt afirma maintain largest market share
revenu roughli
howev would note unabl win languag treatment guidelin
differenti posit guidelin afirma guidelin refer gener use
molecular test believ gener languag treatment guidelin
undermin strength first mover advantag allow later
entrant idxg make rapid gain payor coverag point refer
despit enter market three year afirma enjoy significantli less capit
support commerci adopt payor million cover live posit
coverag opinion thygenext thyramiralmost exactli equal afirma
take afirma appear lose market share thygenext thyramir
growth afirma compar growth total idxg sale
period idxg break sale product disclos pancragen sale
roughli flat impli thygenx thyramir revenu grew significantli faster
afirma medicar price increas roughli
line combin price thygenx thyramir
exhibit comparison molecular test indetermin thyroid nodul
nishino nikiforova updat molecular test cytolog indetermin thyroid nodul archiv patholog laboratori
medicin nikiforova et al analyt perform thyroseq genom classifi cancer diagnosi thyroid nodul cancer
path univers pittsburgh medic center upmc creat joint ventur
commerci thyroseq ngs-base genom classifi indetermin thyroid
nodul group improv perform test nearli ten year
view specif still remain sub-optimal present american
thyroid associ meet januari path introduc thyoseq evalu
mutat fusion gene express alter copi number variat gene
test valid studi indetermin sampl produc npv
ppv
characteristicafirma-gecthyroseq microarray genesng genesmultiplex pcr sampl type fna pass aliquot drop first fna pass aliquot rtsampl kit providedyesyesyescytolog reviewcentralizedloc centralizedloc centralizedfna indet preval thygenx thyramir idxg outperform
take thyroseq perform undifferenti thryamir unlik
gain commerci traction due high cost
sever profession societi issu practic guidelin support use molecular
test follow fna test yield bethesda cytolog commonli known
indetermin result unlik breast cancer prognost test oncotyp dx
secur differenti posit compet assay nearli guidelin pertain
indetermin fna describ use molecular test gener altern
surgeri given practic guidelin typic drive insur coverag commerci
practic generaliz languag guidelin allow new entrant
idxg move quickli secur posit coverag decis note
thygenext thyramir launch nearli three year afirma enjoy nearli
ident insur coverag cover live
sever profession societi guidelin relev adopt
thygenext thyramir focu nation comprehens cancer network
nccn repres largest group practic clinician
repres practic guidelin
nccn first issu guidelin support use molecular test fna reflex test
import updat highlight stronger base evid
support recommend notabl nccn thyroid carcinoma guidelin
recommend
diagnosi follicular carcinoma requir evid either vascular capsular
invas determin fna molecular diagnost may use
allow reclassif follicular lesion follicular neoplasm follicular lesion
undetermin signific flu either less like benign malign
base genet profil molecular test conjunct clinic ultrasound
featur suggest papillari thyroid carcinoma especi case braf
molecular marker interpret caution context clinic
radiograph cytolog featur individu patient nccn guidelin
move in-network drive growth
thyroid franchis cover medic necess opinion plan cover
million live test contract plan result
rel long payment cycl ambigu regard price
take get contract addit nation privat payor import
support next leg growth thygenext thyramir place test
level competit posit rel affirma
would note manag made progress contract discuss includ
sign agreement go network aetna manag current focu
primarili local region bc/b plan
thyroid modelconserv sale
evalu us indetermin fna thyroid test market begin
look total number fna biopsi perform year us accord
analysi present endotext entitl fine-needl aspir biopsi
thyroid gland estim fna perform us base year
assum number fna increas annual base age popul
figur slightli higher cite idxg manag assess
market
estim literatur suggest fna equivoc find show
bethesda categori cytologyatypia undetermin signific follicular lesion
undetermin signific aus/flu bethesda categori iv cytologyfollicular
neoplasm fn suspici fn sfn classifi indetermin result
combin fna market total high end literatur estim
indetermin result yield address market indetermin fna
result annual view maximum address market recogn
patient receiv one fna howev believ reliabl data
quantifi relationship fna test patient subset indetermin
idxg disclos revenu segment compani disclos
thyroid revenu roughli half total revenu financi model use
disclosur subsequ updat growth trend franchis construct revenu
